Although all SSTR subtypes are expressed in NFPA and efficacy is linked to the expression of receptor subtypes, the question of debate is whether it is SSTR1 or SSTR3 that is highly efficacious. The gene discussed is SSTR1; the disease is non-functioning pituitary adenoma.